HPV-positive oropharyngeal squamous cell carcinoma is associated with TIMP3 and CADM1 promoter hypermethylation

Cancer Medicine

Volumn 3, Issue 5, 2014, Pages 1185-1196

  van Kempen, Pauline M W ^a   van Bockel, Liselotte ^a   Braunius, Weibel W ^a   Moelans, Cathy B ^a   van Olst, Marina ^a   de Jong, Rick ^a   Stegeman, Inge ^a   van Diest, Paul J ^a   Grolman, Wilko ^a   Willems, Stefan M ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

CADM1; CHFR; HPV; Hypermethylation; Oropharynx squamous cell carcinoma; TIMP3

Indexed keywords

TISSUE INHIBITOR OF METALLOPROTEINASE 3; CADM1 PROTEIN, HUMAN; CELL ADHESION MOLECULE; IMMUNOGLOBULIN;

ADULT; AGED; ARTICLE; CADM1 GENE; CANCER SURVIVAL; CDH13 GENE; CERVICAL SQUAMOUS CELL CARCINOMA; CHFR GENE; CONTROLLED STUDY; DAPK1 GENE; DNA METHYLATION; FEMALE; GENETIC ASSOCIATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OROPHARYNGEAL SQUAMOUS CELL CARCINOMA; OROPHARYNX CARCINOMA; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROMOTER REGION; RARB GENE; TIMP3 GENE; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA; VERY ELDERLY; WART VIRUS; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; COMPLICATION; GENETICS; MIDDLE AGED; MORTALITY; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PATHOLOGY; PROGNOSIS; RISK FACTOR; TUMOR VOLUME; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL ADHESION MOLECULES; DNA METHYLATION; FEMALE; HUMANS; IMMUNOGLOBULINS; MALE; MIDDLE AGED; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; PROMOTER REGIONS, GENETIC; RISK FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TUMOR BURDEN;

EID: 84942207586     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.313     Document Type: Article

References (56)

1. Leemans, C. R., B. J. Braakhuis, and R. H. Brakenhoff. 2011. The molecular biology of head and neck cancer. Nat. Rev. Cancer 11:9-22.
2. Siegel, R., D. Naishadham, and A. Jemal. 2012. Cancer statistics, 2012. CA Cancer J. Clin. 62:10-29.
3. Conley, B. A. 2006. Treatment of advanced head and neck cancer: what lessons have we learned? J. Clin. Oncol. 24:1023-1025.
4. Smith, E. M., L. M. Rubenstein, T. H. Haugen, E. Hamsikova, and L. P. Turek. 2010. Tobacco and alcohol use increases the risk of both HPV-associated and HPV-independent head and neck cancers. Cancer Causes Control 21:1369-1378.
5. Warnakulasuriya, S. 2009. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 45:309-316.
6. Fakhry, C., W. H. Westra, S. Li, A. Cmelak, J. A. Ridge, H. Pinto, et al. 2008. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl. Cancer Inst. 100:261-269.
7. Ang, K. K., J. Harris, R. Wheeler, R. Weber, D. I. Rosenthal, P. F. Nguyen-Tan, et al., et al. 2010. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363:24-35.
8. Suijkerbuijk, K. P., P. J. van Diest, and E. van der Wall. 2011. Improving early breast cancer detection: focus on methylation. Ann. Oncol. 22:24-29.
9. Jones, P. A., and S. B. Baylin. 2007. The epigenomics of cancer. Cell 128:683-692.
10. Baylin, S. B., and J. G. Herman. 2000. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 16:168-174.
11. Esteller, M. 2008. Epigenetics in cancer. N. Engl. J. Med. 358:1148-1159.
12. Li, K. K., F. Li, Q. S. Li, K. Yang, and B. Jin. 2013. DNA methylation as a target of epigenetic therapeutics in cancer. Anticancer Agents Med. Chem. 13:242-247.
13. Kelly, T. K., D. D. De Carvalho, and P. A. Jones. 2010. Epigenetic modifications as therapeutic targets. Nat. Biotechnol. 28:1069-1078.
14. Colacino, J. A., D. C. Dolinoy, S. A. Duffy, M. A. Sartor, D. B. Chepeha, C. R. Bradford, et al. 2013. Comprehensive analysis of DNA methylation in head and neck squamous cell carcinoma indicates differences by survival and clinicopathologic characteristics. PLoS One 8:e54742.
15. Gubanova, E., B. Brown, S. V. Ivanov, T. Helleday, G. B. Mills, W. G. Yarbrough, et al. 2012. Downregulation of SMG-1 in HPV-positive head and neck squamous cell carcinoma due to promoter hypermethylation correlates with improved survival. Clin. Cancer Res. 18:1257-1267.
16. Kostareli, E., D. Holzinger, O. Bogatyrova, T. Hielscher, G. Wichmann, M. Keck, et al. 2013. HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas. J. Clin. Invest. 123:2488-2501.
17. Dong, S. M., D. I. Sun, N. E. Benoit, I. Kuzmin, M. I. Lerman, and D. Sidransky. 2003. Epigenetic inactivation of RASSF1A in head and neck cancer. Clin. Cancer Res. 9(10 Pt 1):3635-3640.
18. Marsit, C. J., M. D. McClean, C. S. Furniss, and K. T. Kelsey. 2006. Epigenetic inactivation of the SFRP genes is associated with drinking, smoking and HPV in head and neck squamous cell carcinoma. Int. J. Cancer 119:1761-1766.
19. Weiss, D., T. Basel, F. Sachse, A. Braeuninger, and C. Rudack. 2011. Promoter methylation of cyclin A1 is associated with human papillomavirus 16 induced head and neck squamous cell carcinoma independently of p53 mutation. Mol. Carcinog. 50:680-688.
20. Weiss, D., C. Stockmann, K. Schrodter, and C. Rudack. 2013. Protein expression and promoter methylation of the candidate biomarker TCF21 in head and neck squamous cell carcinoma. Cell Oncol. (Dordr) 36:213-224.
21. Lechner, M., T. Fenton, J. West, G. Wilson, A. Feber, S. Henderson, et al. 2013. Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma. Genome Med. 5:15.
22. Sartor, M. A., D. C. Dolinoy, T. R. Jones, J. A. Colacino, M. E. Prince, T. E. Carey, et al. 2011. Genome-wide methylation and expression differences in HPV(+) and HPV(-) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics 6:777-787.
23. van Kempen, P. M., R. Noorlag, W. W. Braunius, I. Stegeman, S. M. Willems, and W. Grolman. 2014. Differences in methylation profiles between HPV-positive and HPV-negative oropharynx squamous cell carcinoma: a systematic review. Epigenetics 9:194-203.
24. van Diest, P. J. 2002. No consent should be needed for using leftover body material for scientific purposes. For. BMJ 325:648-651.
25. Smeets, S. J., A. T. Hesselink, E. J. Speel, A. Haesevoets, P. J. Snijders, M. Pawlita, et al. 2007. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int. J. Cancer 121:2465-2472.
26. Demokan, S., and N. Dalay. 2011. Role of DNA methylation in head and neck cancer. Clin. Epigenetics 2:123-150.
27. Henken, F. E., S. M. Wilting, R. M. Overmeer, J. G. van Rietschoten, A. O. Nygren, A. Errami, et al. 2007. Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. Br. J. Cancer 97:1457-1464.
28. Nygren, A. O., N. Ameziane, H. M. Duarte, R. N. Vijzelaar, Q. Waisfisz, C. J. Hess, et al. 2005. Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res. 33:e128.
29. Joensuu, E. I., W. M. Abdel-Rahman, M. Ollikainen, S. Ruosaari, S. Knuutila, and P. Peltomaki. 2008. Epigenetic signatures of familial cancer are characteristic of tumor type and family category. Cancer Res. 68:4597-4605.
30. Gylling, A., W. M. Abdel-Rahman, M. Juhola, K. Nuorva, E. Hautala, H. J. Jarvinen, et al. 2007. Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study. Gut 56:926-933.
31. Moelans, C. B., A. H. Verschuur-Maes, and P. J. van Diest. 2011. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. J. Pathol. 225:222-231.
32. Suijkerbuijk, K. P., M. J. Fackler, S. Sukumar, C. H. van Gils, T. van Laar, E. van der Wall, et al. 2008. Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer. Ann. Oncol. 19:1870-1874.
33. zur Hausen, H. 2002. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2:342-350.
34. Pillai, R. N., S. A. Brodie, G. L. Sica, Y. Shaojin, G. Li, D. C. Nickleach, et al. 2013. CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC. Clin. Cancer Res. 19:1603-1611.
35. Botling, J., K. Edlund, M. Lohr, B. Hellwig, L. Holmberg, M. Lambe, et al. 2013. Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin. Cancer Res. 19:194-204.
36. Slebos, R. J., N. Jehmlich, B. Brown, Z. Yin, C. H. Chung, W. G. Yarbrough, et al. 2013. Proteomic analysis of oropharyngeal carcinomas reveals novel HPV-associated biological pathways. Int. J. Cancer, 132:568-579.
37. Martinez, I., J. Wang, K. F. Hobson, S. A. Khan. 2007. Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. Eur. J. Cancer 43:415-432.
38. Yalniz, Z., S. Demokan, Y. Suoglu, M. Ulusan, and N. Dalay. 2011. Simultaneous methylation profiling of tumor suppressor genes in head and neck cancer. DNA Cell Biol. 30:17-24.
39. Burgers, W. A., L. Blanchon, S. Pradhan, Y. de Launoit, T. Kouzarides, and F. Fuks. 2007. Viral oncoproteins target the DNA methyltransferases. Oncogene 26:1650-1655.
40. Kim, Y. H., Z. Petko, S. Dzieciatkowski, L. Lin, M. Ghiassi, S. Stain, et al. 2006. CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of colorectal cancer. Genes Chromosom. Cancer 45:781-789.
41. Lui, E. L., W. T. Loo, L. Zhu, M. N. Cheung, and L. W. Chow. 2005. DNA hypermethylation of TIMP3 gene in invasive breast ductal carcinoma. Biomed. Pharmacother. 59(Suppl 2):S363-S365.
42. Bachman, K. E., J. G. Herman, P. G. Corn, A. Merlo, J. F. Costello, W. K. Cavenee, et al. 1999. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res. 59:798-802.
43. Darnton, S. J., L. J. Hardie, R. S. Muc, C. P. Wild, and A. G. Casson. 2005. Tissue inhibitor of metalloproteinase-3 (TIMP-3) gene is methylated in the development of esophageal adenocarcinoma: loss of expression correlates with poor prognosis. Int. J. Cancer 115:351-358.
44. Anand-Apte, B., M. S. Pepper, E. Voest, R. Montesano, B. Olsen, G. Murphy, et al. 1997. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest. Ophthalmol. Vis. Sci. 38:817-823.
45. Han, X., H. Zhang, M. Jia, G. Han, and W. Jiang. 2004. Expression of TIMP-3 gene by construction of a eukaryotic cell expression vector and its role in reduction of metastasis in a human breast cancer cell line. Cell. Mol. Immunol. 1:308-310.
46. Liu, Z., L. Zhu, H. Qin, D. Li, Z. Xie, X. Ke, et al. 2011. Re-expression of cell adhesion molecule inhibits growth and induces apoptosis of human pancreatic cancer cell line PANC-1. J. Huazhong Univ. Sci. Technolog. Med. Sci. 31:762-767.
47. Fukuhara, H., M. Kuramochi, T. Fukami, K. Kasahara, M. Furuhata, T. Nobukuni, et al. 2002. Promoter methylation of TSLC1 and tumor suppression by its gene product in human prostate cancer. Jpn. J. Cancer Res. 93:605-609.
48. Chin, C. F., and F. M. Yeong. 2009. Safeguarding entry into mitosis: the antephase checkpoint. Mol. Cell. Biol. 30:22-32.
49. Paulsson, K., Q. An, A. V. Moorman, H. Parker, G. Molloy, T. Davies, et al. 2009. Methylation of tumour suppressor gene promoters in the presence and absence of transcriptional silencing in high hyperdiploid acute lymphoblastic leukaemia. Br. J. Haematol. 144:838-847.
50. Vogel, C., S. Abreu Rde, D. Ko, S. Y. Le, B. A. Shapiro, S. C. Burns, et al. 2010. Sequence signatures and mRNA concentration can explain two-thirds of protein abundance variation in a human cell line. Mol. Syst. Biol. 6:400.
51. Overmeer, R. M., F. E. Henken, P. J. Snijders, D. Claassen-Kramer, J. Berkhof, T. J. Helmerhorst, et al. 2008. Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC. J. Pathol. 215:388-397.
52. Vogel, C., and E. M. Marcotte. 2012. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 13:227-232.
53. Claus, R., S. Wilop, T. Hielscher, M. Sonnet, E. Dahl, O. Galm, et al. 2012. A systematic comparison of quantitative high-resolution DNA methylation analysis and methylation-specific PCR. Epigenetics 7:772-780.
54. Homig-Holzel, C., and S. Savola. 2012. Multiplex ligation-dependent probe amplification (MLPA) in tumor diagnostics and prognostics. Diagn. Mol. Pathol. 21:189-206.
55. Suijkerbuijk, K. P., X. Pan, E. van der Wall, P. J. van Diest, and M. Vooijs. 2010. Comparison of different promoter methylation assays in breast cancer. Anal. Cell Pathol. (Amst.) 33:133-141.
56. Jeuken, J. W., S. J. Cornelissen, M. Vriezen, M. M. Dekkers, A. Errami, A. Sijben, et al. 2007. MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab. Invest. 87:1055-1065.